Related Experiment Video

Updated: Aug 23, 2026

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

[New therapeutic strategies in severe sepsis and septic shock]

Mauro Oddo1, Marie-Denise Schaller, Thierry Calandra

  • 1Division des Soins Intensifs, Département de Médecine, Interne CHUV, Lausanne. mauro.oddo@chuv.hospvd.ch

Revue Medicale De La Suisse Romande
|August 6, 2004
PubMed

Insights

Severe sepsis and septic shock are leading causes of death. Recent advancements offer five effective therapies, including early goal-directed therapy and intensive insulin therapy, to significantly reduce mortality in these critical conditions.

Area of Science:

  • Critical care medicine
  • Infectious diseases
  • Pathophysiology of sepsis

Context:

  • Severe sepsis and septic shock contribute significantly to global mortality.
  • Limited therapeutic options were historically available despite advances in understanding sepsis.
  • Recent research has focused on developing novel interventions to combat sepsis.

Purpose:

  • To review recently established, evidence-based therapies for severe sepsis and septic shock.
  • To highlight five specific interventions proven effective in large randomized controlled trials.
  • To inform clinicians about current, advanced treatment modalities for sepsis.

Summary:

  • Early goal-directed therapy (EGDT) improves outcomes.
  • Recombinant activated protein C (APC) offers a targeted approach.
  • Moderate-dose corticosteroids may be beneficial in specific cases.
  • Low tidal volume ventilation is crucial for managing acute respiratory distress syndrome (ARDS) in sepsis.
  • Intensive insulin therapy effectively controls hyperglycemia, a common complication.

Impact:

  • These five therapies represent significant progress in managing severe sepsis and septic shock.
  • Implementation of these treatments can lead to reduced mortality rates.
  • Provides clinicians with a more robust therapeutic arsenal against life-threatening sepsis.

More Related Videos

Developing a Clinically Relevant Hemorrhagic Shock Model in Rats08:14

Developing a Clinically Relevant Hemorrhagic Shock Model in Rats

Published on: March 22, 2024

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...